Key regions: United Kingdom, Germany, France, South Korea, Italy
Poland, like many other countries, has been significantly impacted by the COVID-19 pandemic. With the number of cases continuing to rise, the government has been working to secure a steady supply of vaccines to help protect its citizens. Here are some insights into the trends and developments in the COVID-19 Vaccines market in Poland.
Customer preferences: As in many other countries, the Polish government has been prioritizing the vaccination of its most vulnerable citizens, including the elderly and healthcare workers. However, there has been some hesitancy among the general population to get vaccinated, with concerns about side effects and the speed at which the vaccines were developed. The government has been working to address these concerns through public education campaigns and by providing accurate information about the safety and efficacy of the vaccines.
Trends in the market: Poland has been working to secure a steady supply of vaccines from a variety of sources, including the European Union and individual vaccine manufacturers. The government has also been working to ramp up its own production of vaccines, with the hope of being able to produce enough doses to meet the needs of its population. As the vaccination campaign continues, there has been a growing demand for booster shots, which is likely to drive further growth in the market.
Local special circumstances: Poland has a well-developed healthcare system, which has helped to facilitate the distribution of vaccines across the country. However, there have been some logistical challenges in getting vaccines to rural areas and smaller towns. The government has been working to address these challenges by setting up mobile vaccination clinics and other initiatives to reach those who may have difficulty accessing healthcare services.
Underlying macroeconomic factors: Poland has been experiencing a period of economic growth in recent years, which has helped to support the healthcare sector. However, the pandemic has had a significant impact on the economy, with many businesses forced to close and unemployment rates rising. The government has been working to provide support to businesses and individuals affected by the pandemic, which has helped to mitigate some of the economic impact. As the vaccination campaign continues, there is hope that the economy will begin to recover and return to pre-pandemic levels.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
